Novo Nordisk A/S (NYSE: NVO) said at its Capital Markets Day that about 1.5 million people are currently on the Wegovy pill, with sales growth outpacing Eli Lilly’s rival oral drug Foundayo, which was launched a few months later. Company executives added that by 2030, manufacturing capacity for oral Wegovy will grow 10‑fold, and that Novo Nordisk is “exploring and developing further partnerships externally” to secure the flexibility to scale rapidly as demand evolves over the coming years.
Capital Markets Day Snapshot
| Item | Detail |
|---|---|
| Company | Novo Nordisk A/S (NYSE: NVO) |
| Event | Capital Markets Day |
| Date | 21 Sep 2026 |
| Key Disclosure | ≈ 1.5 million people currently on the oral Wegovy pill |
| Competitive Position | Sales growth outpacing Eli Lilly’s Foundayo, launched a few months later |
| Capacity Target | 10‑fold growth in oral Wegovy manufacturing capacity by 2030 |
| Supply Strategy | Exploring and developing further external partnerships for rapid, demand‑driven scaling |
Commercial Evidence – Oral Wegovy vs. Foundayo
| Metric | Status (as of 21 Sep 2026) | Context |
|---|---|---|
| Patients on Oral Wegovy | ≈ 1.5 million | Disclosed at Capital Markets Day |
| Sales Growth vs. Foundayo | Outpacing Eli Lilly’s rival oral drug | Foundayo launched a few months later |
| Absolute Sales Figures | Not disclosed | Growth comparison given qualitatively |
| Market‑Share Details | Not disclosed | – |
The comparison is strategically significant: Foundayo, Eli Lilly’s oral GLP‑1 entrant, reached the market a few months after oral Wegovy, yet Novo Nordisk reports its sales growth trajectory is running ahead of the later‑launched rival — an early indicator of franchise momentum in the fast‑forming oral obesity medication category, where convenience over injectables is expected to dramatically expand the treatable patient pool.
Manufacturing & Supply Chain Strategy
- Capacity Expansion: Manufacturing capacity for oral Wegovy is targeted to grow 10‑fold by 2030, positioning supply to match anticipated long‑term demand for the oral formulation.
- Partnership Flexibility: Management stated the company is “exploring and developing further partnerships externally that will give us the flexibility to scale rapidly depending on how demand is evolving over the coming couple of years” — a hybrid in‑house/external supply model.
- Demand‑Driven Scaling: The partnership language signals Novo Nordisk intends to avoid both supply shortfalls and stranded capacity, adjusting its manufacturing footprint as the oral obesity market matures.
- Partner Identities & Capacity Baselines: Not disclosed.
Market Impact & Outlook
- Oral Incretin Battleground: With ≈ 1.5 million patients already on the pill version of Wegovy and growth outpacing Foundayo, Novo Nordisk is defending its first‑mover position in oral weight‑loss therapy against Eli Lilly in the sector’s most closely watched commercial rivalry.
- Supply as Strategy: The 10‑fold capacity commitment by 2030 — reinforced by external partnerships — addresses the supply constraints that historically limited incretin franchise growth and signals management confidence in sustained oral demand.
- Category Expansion: Oral formulations lower the treatment threshold for patients reluctant to inject, implying the 1.5 million‑user base may represent an early adoption phase rather than a ceiling.
- Investor Watch Items: Quarterly oral Wegovy sales disclosure, Foundayo uptake trends, partnership announcements tied to capacity scaling, and progress toward the 2030 manufacturing target.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding oral Wegovy’s patient uptake, sales growth relative to Foundayo, the 10‑fold manufacturing capacity expansion by 2030, and prospective external partnerships. Actual results may differ due to risks including demand evolution, competitive dynamics in oral obesity therapies, supply‑chain execution, and partnership formation.-Fineline Info & Tech
